RxDoctor Payments Data

Brandon Bader, MD

Cardiovascular Disease · Shenandoah, TXNPI 1710364377

Payments from drug & device makers

$6,599in general payments, 2019–2025

Across 128 payments — averaging $51.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abiomed$1K
  • Terumo Medical Corporation$829
  • Amgen$428
  • Medtronic$417
  • E.r. Squibb & Sons, L.L.C.$267
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$1,50023%
  • Travel & lodging$4597%
  • Food & beverage$4,64070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,599 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$74,732
Medicare patients
224
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$79,531
BrilintaTicagrelor41$24,688
EntrestoSacubitril/Valsartan17$23,272
JardianceEmpagliflozin20$23,067
Repatha SureclickEvolocumab18$16,821
XareltoRivaroxaban12$13,014
Atorvastatin Calcium148$2,723
Metoprolol Succinate118$2,205
Rosuvastatin Calcium73$1,579
Prasugrel Hcl23$1,232
Amlodipine Besylate145$1,214
Torsemide34$1,016
Losartan Potassium41$689
ClopidogrelClopidogrel Bisulfate34$621
Isosorbide Mononitrate ErIsosorbide Mononitrate34$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$79,53182 claims
AstraZenecaBrilinta$142$24,68841 claims
NovartisEntresto$173$23,27217 claims
Boehringer IngelheimJardiance$216$23,06720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →